we conducted a phase i-ii trial of 4-demethoxydaunorubicin ( idarubicin , idr ) in combination with 1-beta-d-arabinofuranosylcytosine ( ara-c ) in 51 patients with relapsed or refractory acute nonlymphocytic leukemia , acute lymphocytic leukemia , or chronic myelogenous leukemia in blast crisis .
C0020789
idarubicin
C0023473
chronic myelogenous leukemia